Personal Information

 Professor

Department of  Pharmacology

Faculty of Pharmacy

Contact Information

Phone: 0126400000 Ext. 22221

Email: ommohamed@kau.edu.sa

Osama Mohamed Ashour Mohamed

 Professor

Profile

Dr Osama M. Ashour is a professor in the Department of Pharmacology and toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, SA. He got his Bachelor Degree in Medicine and Master Degree in Pediatrics from Cairo University, Egypt. He got his Master degree in Pharmacology from the Faculty of Medicine, Minia University, Minia, Egypt. His Master Degree thesis entitled “Some possible interactions between ketamine and pancuronium bromide”.  Then he studied for his Ph.D. Degree in the U.S.  under the Channel System between the University of Alabama at Birmingham (UAB) and Minia University. His Ph.D. thesis entitled “Uridine phosphorylase inhibitors; effective modulators of 5-fluoropyrimidines in cancer chemotherapy”. Dr Ashour has a great experience in teaching Pharmacology to undergraduate and postgraduate students in Medicine, Pharmacy, Dentistry and Nursing Schools. Dr Ashour supervised many Master and Ph.D. theses in Pharmacology. Dr Ashour published his researches in highly impacted journals as well as national journals besides being a reviewer for many highly impacted journals. Dr Ashour is interested in studying the effect of drugs on tumor growth both in vivo in laboratory animals and in vitro (on cultured cell lines). Also, he is interested also in studying the effect of drugs and natural products on experimentally-induced peptic ulcer, diabetes and liver fibrosis.

Education

  • 1981

    Bachelor degree from --Kasr El-Aini Faculty of Medici, Cairo University, القاهرة, مصــــــــر

  • 1987

    Master degree from PediatricsFaculty of Medicine, Cairo University, Egypt, القاهرة, مصــــــــر

  • 1989

    Doctorate degree from Pharmacology DepartmentFaculty of Medicine, Minia University, المنيا, مصــــــــر

  • 1998

    Doctorate degree from Pharmacology and Department ofFaculty of Medicine, Minia University and Universit, المنيا, مصــــــــر

Employment

  • 1982-1983

    Intern, Kasr El-Aini Hospital and Ministry of Health Hospitals, القاهرة, مصــــــــر

  • 1983-1984

    General Physician, Ministry of Defence, القاهرة, مصــــــــر

  • 1984-1989

    Demonstrator of Pharmacology, Pharmacology Department, Faculty of Medicine, المنيا, مصــــــــر

  • 1989-1991

    Assistant Lecturer of Pharmacology, Pharmacology Department, Faculty of Medicine, Minia University, المنيا, مصــــــــر

  • 1991-1996

    Post-Doctoral Fellow, Department of Biochemical Pharmacology - University of Alabama at Birmingham (UAB) - USA, برمنجهام - الاباما, امــريــكـا

  • 1996-1998

    Assistant Lecturer of Pharmacology, Pharmacolgy Department, Faculty of Medicine, Minia University, المنيا, مصــــــــر

  • 1998-2003

    Lecturer of Pharmacology, Pharmacology Department, Faculty of Medicine, Minia University, المنيا, مصــــــــر

  • 2003-2007

    Associate Professor and Acting Chairman of Pharmacology Department, Faculty of Medicine, Minia University, Pharmacology Department, Faculty of Medicine, Minia University, المنيا, مصــــــــر

  • 2007-حاليا

    Associate Professor, Faculty of Pharmacy, King Abdel-Aziz-Jeddah, جده, المملكة العربية السعودية

  • 2012-حاليا

    Professor, Pharmacology Dept., Minia Faculty of Medicine , المنيا, مصــــــــر

  • 2013-حاليا

    Professor, King Abdulaziz Univ., Fac. of Pharmacy, جده, المملكة العربية السعودية

Research Interests

1.

Experiments on cardiovascular system both in vivo and in vitro (blood pressure measurement, isolated perfused rabbit’s heart preparation as well as ECG tracing in experimental animals).


2.

Experiments on gastro-intestinal tract (induction of gastric ulcer by different models in rats).

 

3.

Experimental induction of diabetes in rats and effects of drugs on the oxidative status.

 

4.

Tissue culture, animal toxicity, pharmacokinetics as well as cancer chemotherapy studies.

 

5.

Enzyme assays determining enzyme activity and inhibition constants for enzyme inhibitors.

 

6. Study of the effect of drugs or natural products on experimentally-induced liver fibrosis.

 

 

 

 

 

 

Scientific interests

  • List of Publications
  1. Abdel-Naim AB, Neamatallah T, Eid BG, Esmat A, Alamoudi AJ, Abd El-Aziz GS, Ashour OM. 2-Methoxyestradiol Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats through Inhibition of HIF-1α/TGF-β/Smad2 Axis. Oxid Med Cell Longev 2018, 2018, Article ID 4389484, 12 pages.
  2. Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res. 2017; 8(6): 591-605.
  3. Algandaby MM, Breika RM, Eid BG, Neamatallah TA, Abdel-Naim AB, Ashour OM. Icariin protects against thioacetamide-induced liver fibrosis in rats: Implication of anti-angiogenic and anti-autophagic properties. Pharmacol Rep 2017; 69(4): 616-24.
  4. Algandaby MM, Al-Sawahli MM, Ahmed OAA, Fahmy UA, Abdallah HM, Hattori M, Ashour OM, Abdel-Naim AB. Curcumin-zein nanospheres improve liver targeting and antifibrotic activity of curcumin in carbon tetrachloride-induced mice liver fibrosis. J Biomed Nanotechnol 2016; 12(9): 1746-57.
  5. Algandaby MM, El-Halawany AM, Abdallah HM, Alahdal AM, Nagy AA, Ashour OM, Abdel-Naim AB. Gingerol protects against experimental liver fibrosis in rats via suppression of pro-inflammatory and profibrogenic mediators. Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(4): 419-28.
  6. Aly HA, El-Shitany NA, El-Beshbishy HA, Ashour OM. Ameliorative effect of lycopene against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced rat liver microsomal toxicity: An in vitro study. Toxicol Ind Health 2015; 31(10): 938-50.
  7. Abdallah HM, Abdel-Naim AB, Ashour OM, Shehata IA, Abdel-Sattar EA. Anti-inflammatory activity of selected plants from Saudi Arabia. Z Naturforsch C 2014; 69: 1-9.
  8. Abdallah HM, Mohamed MA, Abdou AM, Hamed MM, Abdel-Naim AB, Ashour OM. Protective effect of Centaurea pallescens Del. against CCl4-induced injury on a human hepatoma cell line (Huh7). Med Chem Res 2013; 22; 5700-5706.
  9. Elberry AA, Refaie SM, Kamel M, Ali T, Darwish H, Ashour OM. Oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats. Ann Saudi Med 2013; 33(1): 57-62.
  10. Ashour OM, Abdel-Naim AB, Abdallah HM, Nagy AA, Mohamadin AM, Abdel-Sattar EA. Evaluation of the potential cardioprotective activity of some Saudi plants against doxorubicin toxicity. Z Naturforsch C 2012; 67(5-6): 297-307.
  11. Abdel-Sattar E, El-Gayed SH, Shehata I, Ashour OM, Nagy AA, Mohamadin AM. Antioxidant and cardioprotective activity of Stachys schemperi vatke against doxorubicin-induced cardiotoxicity. Bulletin of Faculty of Pharmacy, Cairo University 2012; 50: 41-47.
  12. Ibrahim SA, Ashour OM, Abdel Zahir WY, El-Bitar HI. Potential interactions between glimepiride and candesartan in alloxan-induced diabetic rats. J Egypt Soc Toxicol 2012; 45: 21-30.
  13. Elberry AA, Mufti ST, Al-Maghrabi JA, Abdel-Sattar EA, Ashour OM, Ghareib SA, Mosli HA. Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. J Inflamm (Lond) 2011; 8(1): 40.
  14. Ibrahim MY, Ashour OM. Changes in nitric oxide and free radicals levels in rat gastrocnemius muscle during contraction and fatigue. Clin Exp Pharmacol Physiol 2011; 38: 791-795.
  15. Ashour OM, Elberry AA, Alahdal AM, Al Mohamadi AM, Nagy AA, Abdel-Naim AB, Abdel-Sattar EA, Mohamadin AM. Protective effect of bilberry (Vaccinium myrtillus) against doxorubicin-induced oxidative cardiotoxicity in rats. Med Sci Monit 2011; 17(4): BR110-115.
  16. Algandaby MM, Alghamdi HA, Ashour OM, Abdel-Naim AB, Ghareib SA, Abdel-Sattar EA, Hajar AS. Mechanisms of the antihyperglycemic activity of Retama raetam in streptozotocin-induced diabetic rats. Food Chem Toxicol 2010; 48(8-9): 2448-2453.
  17. Elberry AA, Abdel-Naim AB, Abdel-Sattar EA, Nagy AA, Mosli HA, Mohamadin AM, Ashour OM. Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 2010; 48(5): 1178-1184.
  18. Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers, rosiglitazone and metformin, in indomethacin-induced gastric ulcer in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2010; 37(2): 173-177.
  19. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60(5): 373-381.
  20. Ashour OM, Sawan AS. Celecoxib toxicity on rats' thyroid gland. El-Minia Med Bul 2009; 20(1): 26-37.
  21. Morsy M, Ashour O, Amin E, Rofaeil R. Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats. Pharmazie 2009; 64(9): 590-594.
  22. Mohamadin AM, Ashour OM, El-Sherbeny NA, Alahdal AM, Morsy GM, Abdel-Naim AB. Melatonin protects against hydrogen peroxide-induced gastric injury in rats. Clin Exp Pharmacol Physiol 2009; 36(4): 367-372.
  23. Ashour OM, Khalifa MMA, Abdelrahman AM, Geddawy AIM. Modulation of the pathogenesis of diabetic vascular complications by antioxidants in streptozotocin-induced diabetes in rats. El-Minia Med Bul 2008; 19(1): 238-254.
  24. Ashour OM, Fouad AA, Kamel MY, El-Bitar HI. Therapeutic potential of vitamin E and Panax ginseng in experimentally-induced Alzheimer's disease model in rabbits. Alex J Pharm Sci 2007; 21(2): 87-92.
  25. Ismail HA, Khalifa MM, Hassan MK, Ashour OM. Insights in the mechanisms underlying the anti-ulcer activity of nicorandil. Pharmazie 2007; 62(1): 60-66.
  26. Ismail HA, Khalifa MM, Hassan MK, Ashour OM. Investigation of the mechanisms underlying the gastroprotective effect of nicorandil. Pharmacology 2007; 79: 76-85.
  27. Khalifa MMA, Ashour OM, Abdelrahman AM, Fouad AA, Amin EF. Evaluation of systemic effects of ophthalmic instillation of timolol, betaxolol and carteolol for six weeks in rabbits. Alex J Pharm Sci 2006; 20(2): 137-141.
  28. El-Sayed S E-D, Ashour OM. Possible interaction between nitric oxide modulators and calcium channel blockers in indomethacin-induced gastric ulcer in rats. Bull Egypt Soc Physiol Sci 2005; 25(2): 359-378.
  29. Abdelrahman AM, Fouad AA, Ashour OM. Effect of intravenous anesthetics on endothelium-dependent vasodilatation in intact rats. Bull Alex Fac Med 2002; 38(1): 107-111.
  30. Abdel-Ali SA, Ashour OM, Abdel-Haleem, A-B TA. Possible interactions between gentamicin, cefotaxime, ofloxacin and metronidazole with some non-depolarizing neuromuscular blocking drugs on rat phrenic nerve-hemidiaphragm preparation. Al-Azhar Med J 2002; 31(3&4): 394-405.
  31. Khalifa MMA, Hassan MKA, Ashour OM, Heeba GH. Evaluation of the anti-ulcer activity of pibutidine hydrochloride (IT-066); the new histamine H2-receptor antagonist, in cold-restraint stress- and ethanol-induced ulcer models in rats. Al-Azhar Med J 2002; 31(1): 33-47.
  32. Rizk HA, Ashour OM. Rapid colorimetric methods for determining drugs resistance of Mycobacterium tuberculosis in liquid medium. Egypt J Med Microbiol 2001; 10(4): 781-788.
  33. Ashour OM, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2¢,3¢,5¢-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. Cancer Chemother Pharmacol 2000; 46(3): 235-240.
  34. Ashour OM, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the antitumor efficacy of 5-fluoro-2¢-deoxyuridine against murine colon tumor C26-10. Biochem Pharmacol 2000; 60(5): 687-692.
  35. Ashour OM, Naguib FN, Panzica RP, Al Safarjalani ON, el Kouni MH. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2¢,3¢,5¢-tri-O-acetyluridine, a prodrug of uridine. Biochem Pharmacol 2000; 60(3): 427-431.
  36. Ashour OM, Al Safarjalani ON, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy. Cancer Chemother Pharmacol 2000; 45(5): 351-361.
  37. Abdel-Hakim SM, Ashour OM. Differential protective effect of melatonin against experimentally-induced gastric mucosal injury in rats. Bull Egypt Soc Physiol Sci 1999; 19(1): 168-179.
  38. Ibrahim IY, Abdel-Hakim SM, Hassan MKA, Ashour OM. Effect of modulation of nitric oxide and prostaglandin synthesis on the development of experimental gastric ulcers in rats. Bull Egypt Soc Physiol Sci 1999; 19(1): 151-166.
  39. Khalifa MMA, Hassan MKA, Ashour OM, Abdel-Haleem A-B TA. Lipid peroxidation and atherosclerosis: Effect of calcium channel blockers and angiotensin converting enzyme inhibitors. J Egypt Soc Toxicol 1999; 21: 1-8.
  40. Ashour OM, Abdel-Hakim SM, Abdel-Hafiz HM. Effect of the alkali metals; lithium, cesium and rubidium, on serum glucose level and the role of adrenoceptor antagonism in modulating such effects in male albino rats. Al-Azhar Med J 1998; 27(3,4): 571-585.
  41. Ashour OM, Khalifa MMA, Abdel-Raheem MH, el Kouni MH. Evaluation of 5-(phenylselenenyl)acyclouridine (PSAU), a novel uridine phosphorylase inhibitor. Assiut Med J 1997; 21: 31-55.
  42. Ashour OM, Naguib FNM, el Kouni MH. 5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2¢,3¢,5¢-triacetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Biochem Pharmacol 1996; 51: 1601-1611.
  43. Sommadossi J-P, Cretton EM, Kidd LB, McClure HM, Anderson DC, el Kouni MH. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy. Cancer Chemother Pharmacol 1995; 37: 14-22. (Acknowledged)
  44. Ashour OM, Naguib FN, Khalifa MM, Abdel-Raheem MH, Panzica RP, el Kouni MH. Enhancement of 5-fluoro-2¢-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. Cancer Res 1995; 55(5): 1092-1098.
  45. Naguib FNM, Ashour OM, Schinazi RF, MMA, Abdel-Raheem MH, el Kouni MH. Effect of 5(phenylselenenyl)acyclouridine (PSAU) on plasma uridine concentration in female CD-1 mice. FASEB J 1994; 8: A95 (553). [Abstract]
  46. Ashour OM, Naguib FNM, Khalifa MMA, Abdel-Raheem MH, el Kouni MH. Inhibition constants of 5-(benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA) for hepatic uridine phosphorylase (UrdPase) from different species. FASEB J 1994; 8: A95 (552). [Abstract]
  47. Naguib FNM, Levesque DL, Wang E-C, Panzica RP, el Kouni MH. 5-benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem Pharmacol 1993; 46(7): 1273-1283. (Acknowledged)
  48. Ashour OM, Guarcello V, Khalifa MMA, Abdel-Raheem MH, Naguib FNM, Panzica RP, el Kouni MH. Elevation of plasma uridine by the uridine phosphorylase (UrdPase) inhibitor 5- (benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA) in mice. Pharmacologist 1993; 35: 365.
  49. Ashour OM, Abdel-Raheem MH, El-Bitar HIA. Some possible (cardiovascular) interactions between ketamine HCl and pancuronium Br. Annual conference of the Egyptian Society of Pharmacology and Experimental Therapeutics; 1989.

Courses

Pharmcology 301 PT
Basic and Clinical Toxicology 521 PT
Biostatistics 511 PT

Areas of expertise

Pharmacology and Toxicology
King Abdulaziz University, Jeddah
Teaching Pharmacology and Toxicology Teaching Pharmacology and Toxicology to both undergraduate as well as postgraduate students in Medicine, Pharmacy, Dentistry and Nursing schools.